PD 0183812
Alternative Names: PD 183812; PD0183812Latest Information Update: 22 Aug 2002
At a glance
- Originator Onyx Pharmaceuticals
- Class Antineoplastics; Pyridones; Pyrimidines
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Aug 2002 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 28 Jun 2000 Preclinical development for Cancer in USA (Unknown route)